Key Points
- EVP Shannon Parisotto sold 5,046 CRL shares for approximately $1.33 million at an average price of $263. The transaction occurred under a pre-arranged Rule 10b5-1 plan, leaving her with 4,807 shares.
- Charles River exceeded quarterly expectations, reporting adjusted EPS of $3.02 versus the $2.77 consensus and revenue of about $1 billion, despite a 2.7% year-over-year revenue decline.
- Management raised its fiscal 2026 outlook to adjusted EPS of $11.15–$11.45 and increased its free-cash-flow forecast to $400 million–$420 million, citing improving biotech demand, backlog and cost-reduction benefits.
Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report) EVP Shannon Parisotto sold 5,046 shares of the business's stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $263.00, for a total value of $1,327,098.00. Following the completion of the sale, the executive vice president owned 4,807 shares of the company's stock, valued at $1,264,241. This trade represents a 51.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Charles River Laboratories International Trading Up 1.9%
Shares of NYSE:CRL opened at $265.73 on Friday. The business's 50 day moving average price is $213.14 and its 200-day moving average price is $188.71. Charles River Laboratories International, Inc. has a 1 year low of $144.26 and a 1 year high of $268.00. The firm has a market capitalization of $12.80 billion, a price-to-earnings ratio of -54.79, a price-to-earnings-growth ratio of 2.86 and a beta of 1.38. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.03.
Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, topping analysts' consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The company had revenue of $1 billion during the quarter, compared to analysts' expectations of $980.53 million. During the same period in the prior year, the business posted $3.12 earnings per share. The firm's revenue for the quarter was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, equities research analysts forecast that Charles River Laboratories International, Inc. will post 11.23 earnings per share for the current fiscal year.
Trending Headlines about Charles River Laboratories International
Here are the key news stories impacting Charles River Laboratories International this week:
- Positive Sentiment: Q2 results exceeded expectations: Charles River reported adjusted earnings of $3.02 per share, above the $2.77 consensus estimate, while revenue of approximately $1.0 billion topped expectations of $977.2 million. The earnings beat came despite revenue declining 2.7% year over year. Charles River Q2 earnings report
- Positive Sentiment: Full-year guidance was raised: Management now expects fiscal 2026 adjusted EPS of $11.15-$11.45, above the $11.09 consensus estimate, and revenue of roughly $3.9 billion versus Wall Street expectations of $3.8 billion. The company also raised its free-cash-flow forecast to $400 million-$420 million. Charles River 2026 outlook
- Positive Sentiment: Demand trends are improving: Charles River cited stronger biotech demand for its discovery and development services. Analysts highlighted improving organic revenue and order trends, strong backlog and book-to-bill performance in the Discovery and Safety Assessment segment, and anticipated margin benefits from divestitures and cost reductions. Charles River lifts profit forecast
- Positive Sentiment: JPMorgan upgraded CRL: JPMorgan moved its rating from “neutral” to “overweight” and raised its price target to $310 from $180, signaling greater confidence in the company’s recovery and earnings trajectory.
- Neutral Sentiment: Executive stock sale: EVP Shannon M. Parisotto sold 5,046 shares for approximately $1.33 million under a pre-arranged Rule 10b5-1 trading plan. Although the sale reduced her direct holdings by more than half, the planned nature of the transaction makes it a limited near-term signal about management’s outlook. SEC insider transaction filing
- Negative Sentiment: Underlying risks remain: Quarterly EPS fell from $3.12 a year earlier, revenue declined year over year, and the Resources Management Services segment continues to face weakness in the U.S. These issues could limit the durability of the rally if demand improvement slows.
Institutional Trading of Charles River Laboratories International
Several institutional investors have recently made changes to their positions in CRL. Cardinal Capital Management boosted its holdings in Charles River Laboratories International by 0.6% in the fourth quarter. Cardinal Capital Management now owns 10,928 shares of the medical research company's stock worth $2,180,000 after purchasing an additional 62 shares during the period. Asset Management One Co. Ltd. lifted its position in shares of Charles River Laboratories International by 4.0% in the 4th quarter. Asset Management One Co. Ltd. now owns 1,847 shares of the medical research company's stock worth $375,000 after buying an additional 71 shares during the last quarter. Glenmede Trust Co. NA lifted its position in shares of Charles River Laboratories International by 2.8% in the 1st quarter. Glenmede Trust Co. NA now owns 2,706 shares of the medical research company's stock worth $467,000 after buying an additional 73 shares during the last quarter. Mercer Global Advisors Inc. ADV boosted its holdings in shares of Charles River Laboratories International by 1.3% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 6,316 shares of the medical research company's stock valued at $1,260,000 after buying an additional 80 shares during the period. Finally, Advisory Services Network LLC boosted its holdings in shares of Charles River Laboratories International by 2.6% in the 3rd quarter. Advisory Services Network LLC now owns 3,226 shares of the medical research company's stock valued at $505,000 after buying an additional 83 shares during the period. Hedge funds and other institutional investors own 98.91% of the company's stock.
Wall Street Analyst Weigh In
CRL has been the topic of several research analyst reports. Sanford C. Bernstein set a $250.00 price objective on Charles River Laboratories International in a report on Wednesday, July 1st. Weiss Ratings upgraded Charles River Laboratories International from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, July 1st. Royal Bank Of Canada lifted their price target on Charles River Laboratories International from $215.00 to $282.00 and gave the stock an "outperform" rating in a research note on Thursday. Citigroup reiterated a "buy" rating on shares of Charles River Laboratories International in a research report on Wednesday, July 8th. Finally, Mizuho increased their price objective on Charles River Laboratories International from $192.00 to $230.00 and gave the company a "neutral" rating in a research note on Monday, July 13th. Twelve analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $244.19.
Read Our Latest Stock Report on CRL
Charles River Laboratories International Company Profile
(
Get Free Report)
Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.
Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
